Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 9088 results

  1. Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]

    In development Reference number: GID-TA11484 Expected publication date:  08 July 2026

  2. Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy (review of TA901) [ID6610]

    In development Reference number: GID-TA11850 Expected publication date:  09 July 2026

  3. Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis [ID6487]

    In development Reference number: GID-TA11628 Expected publication date:  09 July 2026

  4. Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]

    In development Reference number: GID-TA10981 Expected publication date:  09 July 2026

  5. Perioperative care in adults

    In development Reference number: GID-QS10094 Expected publication date:  01 July 2026

  6. Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor [ID6269]

    In development Reference number: GID-TA11298 Expected publication date:  01 July 2026

  7. Atogepant for treating migraine [ID6615]

    In development Reference number: GID-TA11817 Expected publication date:  30 June 2026

  8. Deuruxolitinib for treating severe alopecia areata [ID6597]

    In development Reference number: GID-TA11804 Expected publication date:  15 July 2026

  9. Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA779) [ID6326]

    In development Reference number: GID-TA11764 Expected publication date:  23 July 2026

  10. Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457]

    In development Reference number: GID-TA11576 Expected publication date:  18 June 2026

  11. Leg ulcer infection: antimicrobial prescribing (NG152)

    This guideline sets out an antimicrobial prescribing strategy for adults with leg ulcer infection. It aims to optimise antibiotic use and reduce antibiotic resistance.

  12. Impetigo: antimicrobial prescribing (NG153)

    This guideline sets out an antimicrobial prescribing strategy for adults, young people and children aged 72 hours and over with impetigo. It aims to optimise antibiotic use and reduce antibiotic resistance.

  13. Neonatal parenteral nutrition (NG154)

    This guideline covers parenteral nutrition (intravenous feeding) for babies born preterm, up to 28 days after their due birth date and babies born at term, up to 28 days after their birth. Parenteral nutrition is often needed by preterm babies, critically ill babies, and babies who need surgery.

  14. Workplace health: long-term sickness absence and capability to work (NG146)

    This guideline covers how to help people return to work after long-term sickness absence, reduce recurring sickness absence, and help prevent people moving from short-term to long-term sickness absence.

  15. Indoor air quality at home (NG149)

    This guideline covers indoor air quality in residential buildings. It aims to raise awareness of the importance of good air quality in people's homes and how to achieve this.